Prenatal Delivery of Enzyme Replacement Therapy to Fetuses Affected by Early‐Onset Lysosomal Storage Diseases
American Journal of Medical Genetics Part C: Seminars in Medical Genetics · 2025
DOI: 10.1002/ajmg.c.32132 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 2025. Verfasst von Beltran Borges und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of California San Francisco, San Francisco, California, USA. Hauptthemen laut MEDLINE: Enzyme Replacement Therapy, Lysosomal Storage Diseases. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 132 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
The expansion of prenatal genetic screening and diagnosis warrants the evaluation of approved postnatal therapies that may be safely and feasibly translated to prenatal administration to a fetus affected by monogenic disease. For lysosomal storage diseases (LSDs), enzyme replacement therapy (ERT) often represents the main therapeutic approach. In utero enzyme replacement therapy (IUERT) has several potential benefits compared to postnatal therapy, such as: (1) delivering enzyme before the onset of irreversible organ damage; (2) developing tolerance toward the recombinant enzyme; and (3) targeting the central nervous system through a more permeable blood–brain barrier. In this review, we examine the general and disease‐specific rationale for IUERT, and provide an overview of the main elements of our current clinical trial for the prenatal treatment of early‐onset lysosomal storage diseases. Trial Registration: IUERT clinical trial: NCT04532047; Alpha thalassemia clinical trial: NCT02986698
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, University of California San Francisco, San Francisco, California, USA.
- UCSF Center for Maternal-Fetal Precision Medicine, San Francisco, California, USA.
- Department of Pediatrics, Division of Medical Genetics, University of California San Francisco, San Francisco, California, USA.
- Department of Obstetrics, Gynecology and Reproductive Sciences, University of California San Francisco, San Francisco, California, USA.
- Department of Pediatrics, Division of Medical Genetics, Duke University, Durham, North Carolina, USA.
- Department of Pediatrics, Division of Gastroenterology, University of California San Francisco, San Francisco, California, USA.
ORCID-Profile: Beltran Borges, Jennifer L Cohen
Förderung
- NICHD NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Borges, B., Canepa, E., Chang, I. J., Herzeg, A., Lianoglou, B., Kishnani, P. S., Harmatz, P., MacKenzie, T. C., & Cohen, J. L. (2025). Prenatal Delivery of Enzyme Replacement Therapy to Fetuses Affected by Early‐Onset Lysosomal Storage Diseases. American Journal of Medical Genetics Part C: Seminars in Medical Genetics. https://doi.org/10.1002/ajmg.c.32132
Vancouver
Borges B, Canepa E, Chang IJ, Herzeg A, Lianoglou B, Kishnani PS, et al. Prenatal Delivery of Enzyme Replacement Therapy to Fetuses Affected by Early‐Onset Lysosomal Storage Diseases. American Journal of Medical Genetics Part C: Seminars in Medical Genetics. 2025. doi:10.1002/ajmg.c.32132
BibTeX
@article{Borges2025,
author = {Borges, Beltran and Canepa, Emma and Chang, Irene J and Herzeg, Akos and Lianoglou, Billie and Kishnani, Priya S and Harmatz, Paul and MacKenzie, Tippi C and Cohen, Jennifer L},
title = {Prenatal Delivery of Enzyme Replacement Therapy to Fetuses Affected by Early‐Onset Lysosomal Storage Diseases},
journal = {American Journal of Medical Genetics Part C: Seminars in Medical Genetics},
year = {2025},
doi = {10.1002/ajmg.c.32132}
}
EUVIMED